Posters

Mar 2023

ELCC – Mini Oral Presentation

Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC patients resistant to PD-1/PD-L1 inhibitors

Nov 2022

SITC – Late-Breaking Abstract, Oral Presentation

Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

Nov 2022

SITC

TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma

Nov 2022

SITC

Feasibility of eftilagimod alpha (soluble LAG-3 protein) combined with standard-of-care therapy in advanced non-small-cell lung cancer (NSCLC) adenocarcinomas – Initial results from INSIGHT 003

Aug 2022

IASLC World Conference on Lung Cancer

Results from a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma (NSCLC) patients

Publications

AIPAC: A Phase Iib Study of Eftilagimod Alpha (Imp321 or Lag-3Ig) Added to Weekly Paclitaxel In Patients With Metastatic Breast Cancer

Lux Dirix & Frederic Triebel, April 2019, Pages 1963-1973, https://doi.org/10.2217/fon-2018-0807

P449 Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial

Ellis, Marks, Barrett, Hopkins, Richards, Fuhr, Albayaty et al. Journal of Crohn’s and Colitis, Volume 13, Issue Supplement_1, March 2019, Page S336, https://doi.org/10.1093/ecco-jcc/jjy222.573

Combination of paclitaxel and LAG-3lg (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): interim results from the run-in phase of a placebo controlled randomized phase II.

Duhoux FP, Jager A, Dirix L, Huizing MT, Jerusalem G, Vuylsteke P, De Cuypere E, Breiner D, Mueller, Brignone C and Triebel F. 2017. Journal of Clinical Oncology 35:1062.

Immunotherapy earns its spot in the ranks of cancer therapy.

Pardoll D. and Drake C.. 2012. J Exp Med 209:2.

Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+)-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates

N Poirier, T Haudebourg, C Brignone, N Dilek, J Hervouet, D Minault, F Coulon, R V de Silly, F Triebel, G Blancho, B Vanhove May 2011 Clinical and Experimental Immunology, Volume 164, Issue 2